Uncork Capital avoids health startups requiring upfront FDA approval
Andy McLoughlin · 20VC: Andy McLoughlin on The Benefits of Backing Unsexy Businesses with Non-Obvious Founders, How To Distinguish Between A Good Bridge Round and A Bridge To Nowhere & Whether VCs Really Do Add Value? · May 8, 2018 · at 21:41
Andy McLoughlin, Partner at Uncork Capital, describes the firm's investment strategy regarding regulatory risk in digital health and health hardware.
“Yeah, I mean, I think we stay clear of anything which is too highly regulated. I mean, we do a lot of look at digital health. We look at hardware and health, and in any of these areas, we try and find products that don't necessarily need FDA approval, in order to go to market initially, they may do so for a future version of the product or, you know, a future product line, but we don't want that to be a stumbling block.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →